SCM
DNTH icon

Sterling Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Sterling Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.7K Sell
1,105
-192
-15% -$11.1K ﹤0.01% 1417
2025
Q4 		$53.4K Buy
1,297
+258
+25% +$10K ﹤0.01% 1777
2025
Q3 		$40.9K Buy
1,039
+553
+114% +$14.1K ﹤0.01% 1832
2025
Q2 		$9.05K Buy
486
+102
+27% +$1.91K ﹤0.01% 2190
2025
Q1 		$6.97K Sell
384
-327
-46% -$7.21K ﹤0.01% 2001
2024
Q4 		$15.5K Buy
711
+633
+812% +$16.3K ﹤0.01% 1958
2024
Q3 		$2.14K Buy
+78
New +$2.17K ﹤0.01% 2155

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sterling Capital Management's DNTH Position: Q1 2026 in Review

Sterling Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 15% in Q1 2026, selling an estimated $11.1K and leaving 1,105 shares worth $92.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Sterling Capital Management first reported a position in DNTH in Q3 2024 and has held it in 7 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Sterling Capital Management held 1,105 shares of Dianthus Therapeutics worth $92.7K as of Q1 2026.
  • Sterling Capital Management sold 192 Dianthus Therapeutics shares in Q1 2026, an estimated $11.1K.
  • Dianthus Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1417 holding.
  • Sterling Capital Management first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.